Drugs / ZYT1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01543269 Comparator | Feb 2010 → Jul 2012 | lip disorder, obesity disorder | Zydus Lifesciences Limited | Terminated | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-04-02 | Zydus Lifesciences Limited | Zydus files IND application with the USFDA for ZYT1 a novel candidate to treat dyslipidemia zyduslife.com ↗ |
| 2008-10-16 | Zydus Lifesciences Limited | Zydus files IND application for ZYT1 a novel candidate to treat dyslipidemia zyduslife.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYT1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01543269 ↗ |
| Action | Activate | “ZYT1, a Selective Thyroid Receptor (TR) ß Agonist” NCT01543269 ↗ |
| Route | Oral | “Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.” NCT01543269 ↗ |